New York Office | email@example.com
Jie Liu, a Managing Director at Torreya, leads the company’s operations in China. He has over 20 years of experience in the pharmaceutical and healthcare industries, mostly focused on global licensing and M&A. In his current role, Jie is active in a variety of transactions in both branded and generic opportunities in the US and China.
Jie joined Torreya in 2016 from Heritage Pharma, a subsidiary of Emcure Pharmaceuticals, where he was Vice President, Business Development and Licensing. Previously, he was Senior Director, Global Business Development at Teva, and held business development positions with increasing responsibilities at J&J, Cephalon, and Auxilium.
Notable transactions on which Jie advised prior to joining Torreya include Teva’s $3.5 billion acquisition of Auspex; Teva’s acquisition of Labrys Biologics for up to $825 million, including $200 million upfront; Teva’s collaboration with Microchips in implantable medical device for $35 million in equity investment and technology access fee; Testim co-promote between Auxilium and GSK; Provigil co-promote between Cephalon and Takeda; Cephalon’s $350 million stem cell deal with Mesoblast for $130 million upfront and a $220 million equity stake; Cephalon’s acquisition of ChemGenex for $231 million; and Cephlaon’s acquisition of Salmedix for $160 million.
Jie received a B.A. from Tianjin University in China and an M.B.A. in healthcare from the Wharton School at the University of Pennsylvania. Jie is a native Mandarin speaker, and is licensed in the US as a speech pathologist.
|Divestiture of China right of Sai Bo Song™ (buprenorphine, naloxone) tablet to|
Up to $122.5 million
|JV Partnership |
in China with
|License of Durasert™ in opthalmololgy in the Greater China Region to|
Up to $11.75 million
|License of AJT-240 in hemodialysis in China to|
Up to $24 million